The Food and Drug Administration Feb. 5 released an alert notifying patients of a safety concern using diabetes devices such as continuous glucose monitors, insulin pumps and automated insulin dosing systems that rely on a smartphone for delivering alerts. The agency said it received medical device reports in which users reported alerts were not being delivered or heard in situations where the users thought they configured the alerts to be delivered. Some instances may have contributed to serious harm, including severe hypoglycemia, severe hyperglycemia, diabetic ketoacidosis and death.   

The FDA issued recommendations for users and said it is working with diabetes-related medical device manufacturers to ensure that smartphone alert configurations are evaluated prior to use. It is also working with manufacturers to ensure settings for smartphones and mobile medical applications are continuously tested and that updates are communicated quickly and clearly to users.

Related News Articles

Headline
John Riggi, AHA national advisor for cybersecurity and risk, talks with Brett Leatherman, FBI assistant director, Cyber Division, and Gretchen Burrier, FBI…
Headline
The AHA Feb. 9 released a series of behavioral threat assessment and management resources developed in partnership with the FBI’s Behavioral Analysis Unit-1.…
Headline
A new tactical brief on technology-enabled care explores key trends, innovations and learnings, and provides considerations for how hospitals can…
Headline
John Riggi, AHA national advisor for cybersecurity and risk, talks with Brett Leatherman, FBI assistant director, Cyber Division, and Gretchen Burrier, FBI…
Headline
The National Institute of Standards and Technology Feb. 2 published details on a critical vulnerability that impacted Notepad++, a free, open-source text and…
Headline
The Assistant Secretary for Technology Policy/Office of the National Coordinator for Health Information Technology released a request for information Jan. 29…